These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 24976117)
21. India's decision on Gleevec: implications for the future. Wilensky GR Healthc Financ Manage; 2013 May; 67(5):32-3. PubMed ID: 23678685 [No Abstract] [Full Text] [Related]
22. Drug patents: innovation v. accessibility. Collier R CMAJ; 2013 Jun; 185(9):E379-80. PubMed ID: 23630237 [No Abstract] [Full Text] [Related]
23. Drug patents cause fresh spat between South Africa and industry. Jack A BMJ; 2014 Feb; 348():g1377. PubMed ID: 24511092 [No Abstract] [Full Text] [Related]
24. Final hearings begin in epic legal battle over Novartis drug in India. Mudur G BMJ; 2012 Sep; 345():e6257. PubMed ID: 22991008 [No Abstract] [Full Text] [Related]
25. Patents: a threat to innovation? Manocaran M Science; 2010 Jan; 327(5961):31-2; author reply 32. PubMed ID: 20044557 [No Abstract] [Full Text] [Related]
26. Reach-through claims for drug target patents: Rx for pharmaceutical policy. Bohrer RA Nat Biotechnol; 2008 Jan; 26(1):55-6. PubMed ID: 18183015 [No Abstract] [Full Text] [Related]
27. Drug patents: the evergreening problem. Collier R CMAJ; 2013 Jun; 185(9):E385-6. PubMed ID: 23630239 [No Abstract] [Full Text] [Related]
28. "To patent or not to patent? the case of Novartis' cancer drug Glivec in India". Gabble R; Kohler JC Global Health; 2014 Jan; 10():3. PubMed ID: 24393270 [TBL] [Abstract][Full Text] [Related]
29. Indian biogenerics industry emerges. Jayaraman KS Nat Biotechnol; 2003 Oct; 21(10):1115-6. PubMed ID: 14520378 [No Abstract] [Full Text] [Related]
30. Issues in Indian science. Byravan S Science; 2005 Jul; 309(5734):557-8; author reply 557-8. PubMed ID: 16044529 [No Abstract] [Full Text] [Related]
32. Obviousness, hindsight and perspective: the impact of KSR v. Teleflex on biotech and pharmaceutical patents. Teitelbaum R; Cohen M Nat Biotechnol; 2007 Oct; 25(10):1105-6. PubMed ID: 17921990 [No Abstract] [Full Text] [Related]
33. How high is too high for the threshold on patent utility? Sklan A Pharm Pat Anal; 2012 Jul; 1(3):237. PubMed ID: 24236834 [No Abstract] [Full Text] [Related]
35. Court dismisses Novartis challenge to Indian patent law. Mudur G BMJ; 2007 Aug; 335(7614):273. PubMed ID: 17690349 [No Abstract] [Full Text] [Related]
36. Biotech patents-business as usual? Lawrence S Nat Biotechnol; 2008 Dec; 26(12):1326. PubMed ID: 19060861 [No Abstract] [Full Text] [Related]
37. Patent protection in Europe of pharmaceuticals found to have a further medical indication. Cockbain J Pharm Pat Anal; 2012 Mar; 1(1):17-8. PubMed ID: 24236708 [No Abstract] [Full Text] [Related]
38. The emerging effects of the Drug Price Competition and Patent Term Restoration Act of 1984. Lewis RA J Contemp Health Law Policy; 1992; 8():361-78. PubMed ID: 10118987 [No Abstract] [Full Text] [Related]
39. The challenge to patent law of pure chemical protein synthesis. Fellmeth AX Nat Biotechnol; 2005 May; 23(5):547-9. PubMed ID: 15877067 [No Abstract] [Full Text] [Related]